JACK-MA/ALIBABA-FOUND
26.3.2020 04:45:09 CET | Business Wire | Press release
Over 440 medical institutions from 104 countries and regions have applied to learn and share experiences in battling COVID-19 through the International Medical Expert Communication Platform . The Handbook of COVID-19 Prevention and Treatment is now available in seven languages with more to come.
The platform, a centerpiece of the Global MediXchange for Combating COVID-19 (GMCC) program, was jointly established by the Jack Ma Foundation and Alibaba Foundation. It is designed for medical experts around the world to communicate seamlessly with each other to share their invaluable experience of fighting coronavirus disease 2019 (COVID-19) and to ask and answer each other’s questions. To date, the most applications have come in thus far from medical institutions in the U.S, Turkey, the U.K., Pakistan, Spain and Germany.
Medical staff need to apply and be approved to join the platform. Once they’re accepted, they’re free to participate in individual or group discussions and sessions.
“Knowledge is power! We launched an online platform for doctors and nurses around the world to exchange ideas, lessons and know-how to fight the virus. We welcome all hospitals to join Chinese hospitals on this open platform https://covid-19.alibabacloud.com . One world, one fight!" Jack Ma wrote in a tweet Wednesday.
Tapping Alibaba Group’s DingTalk messaging and communications functions, the digital platform provides free audio and video conference functionality, along with live broadcast functions for more-complex scenarios. Medical workers from different countries can choose to communicate with their fellow doctors individually, or they can participate in live-sharing group sessions to interact with multiple participants, using real-time artificial intelligence translation to overcome communication barriers. The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), for example, has been using the platform to share their valuable experience with 92 medical institutions from 44 countries and regions.
A playback function allows further sharing or posting on official websites for consumption anytime – and for those who can’t join the live broadcasts due to the time difference or if they are occupied by their duties.
To date, the International Medical Expert Communication Platform has attracted numerous Chinese medical institutions, including Zhongnan Hospital of Wuhan University (Wuhan Leishenshan Hospital), The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), and others.
Through video conferencing and AI translation from and into 11 languages (Arabic, Chinese, English, French, Indonesian, Japanese, Russian, Spanish, Thai, Turkish, and Vietnamese), the platform aims to build a virtual community.
DingTalk, which powers this platform, has also been tabbed by UNESCO as facilitating distance learning during the coronavirus outbreak.
Also as part of the GMCC programme, the Handbook of COVID-19 Prevention and Treatment , authored by The First Affiliated Hospital, Zhejiang University School of Medicine and compiled according to clinical experience, is now available at no cost in Chinese, English, French, Italian, Japanese, Turkish and Spanish. This handbook provides comprehensive guidelines and best practices by China's top experts for coping with COVID-19. More languages will be added soon, as the GMCC programme continues to launch more anti-epidemic resources and provide more practical suggestions and references for medical staff worldwide.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200325005799/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom